CR20120359A - Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) - Google Patents

Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)

Info

Publication number
CR20120359A
CR20120359A CR20120359A CR20120359A CR20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A
Authority
CR
Costa Rica
Prior art keywords
erythemate
sle
treatment
humanized antibodies
system lupus
Prior art date
Application number
CR20120359A
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Roettgen
Benjamin Daelken
Andre Engling
Chantal Zuber
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CR20120359A publication Critical patent/CR20120359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un anticuerpo humanizado o quimérico o su frangmento, cpaz de ligar a interleucina-10 (IL-10), en donde el anticuerpo o su fragmento: (i) liga a la misma región de IL-10 que el receptor IL-10a (IL-10Ra) y no es capaz de ligar IL-10 cuando IL-10 se liga al receptor.
CR20120359A 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) CR20120359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
CR20120359A true CR20120359A (es) 2013-01-25

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20120359A CR20120359A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Country Status (17)

Country Link
US (4) US8956607B2 (es)
EP (2) EP2470208A1 (es)
JP (2) JP6005519B2 (es)
KR (2) KR101802260B1 (es)
CN (2) CN102811736B (es)
AU (2) AU2010323036B2 (es)
BR (2) BR112012012912A2 (es)
CA (2) CA2782004A1 (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120359A (es)
IL (2) IL219954A (es)
MX (2) MX343228B (es)
NZ (2) NZ600899A (es)
RU (2) RU2581812C2 (es)
SG (2) SG10201407935YA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012012912A2 (pt) 2009-11-30 2016-10-25 Biotest Ag anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
CN105658232A (zh) 2013-08-30 2016-06-08 阿尔莫生物科技股份有限公司 使用白细胞介素-10治疗疾病和病症的方法
EP3068425B1 (en) 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160356794A1 (en) * 2014-02-10 2016-12-08 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
WO2016083417A1 (en) * 2014-11-28 2016-06-02 Ge Healthcare Bio-Sciences Ab Method for determining analyte-ligand binding on a sensor surface
CN107108728A (zh) * 2014-12-15 2017-08-29 莫佛塞斯公司 Il‑17c的抗体
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
CA2986755A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
US10398761B2 (en) 2015-08-25 2019-09-03 Armo Biosciences, Inc. Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers
UY37003A (es) 2015-12-04 2017-06-30 Novartis Ag Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
AU2022242840A1 (en) * 2021-03-23 2023-09-28 Organogenesis, Inc. Methods kits and compositions for characterizing an anti-inflammatory response of a product
KR20240114801A (ko) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
MY108267A (en) * 1991-01-16 1996-09-30 Schering Corp Use of interleukin-10 in adoptive immunotherapy of cancer
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
WO1993002693A2 (en) 1991-08-06 1993-02-18 Schering Corporation Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
EP3263596A1 (en) * 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
PE20050925A1 (es) * 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
CN111909273B (zh) * 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
BR112012012912A2 (pt) * 2009-11-30 2016-10-25 Biotest Ag anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.

Also Published As

Publication number Publication date
RU2581812C2 (ru) 2016-04-20
CA2782007C (en) 2018-07-24
SG10201407936XA (en) 2015-01-29
US20150218270A1 (en) 2015-08-06
US20150064179A1 (en) 2015-03-05
CO6561779A2 (es) 2012-11-15
MX343228B (es) 2016-10-26
WO2011064398A1 (en) 2011-06-03
AU2010323036A1 (en) 2012-07-19
NZ600894A (en) 2014-09-26
US20120321618A1 (en) 2012-12-20
MX2012006197A (es) 2012-06-19
IL219954A (en) 2016-10-31
US8852871B2 (en) 2014-10-07
CN102811736A (zh) 2012-12-05
CN102811736B (zh) 2016-01-20
AU2010323037B2 (en) 2015-01-29
CA2782004A1 (en) 2011-06-03
JP6005519B2 (ja) 2016-10-12
IL219955A0 (en) 2012-07-31
EP2470208A1 (en) 2012-07-04
KR101802260B1 (ko) 2017-11-28
BR112012012912A2 (pt) 2016-10-25
US8956607B2 (en) 2015-02-17
CA2782007A1 (en) 2011-06-03
KR101802261B1 (ko) 2017-11-28
CN102711829A (zh) 2012-10-03
EP2470209A1 (en) 2012-07-04
WO2011064399A1 (en) 2011-06-03
RU2587622C2 (ru) 2016-06-20
KR20120103664A (ko) 2012-09-19
CR20120358A (es) 2013-01-23
AU2010323036B2 (en) 2015-01-29
AU2010323037A1 (en) 2012-07-19
IL219955A (en) 2016-08-31
US20120321617A1 (en) 2012-12-20
CN102711829B (zh) 2016-03-16
KR20120115289A (ko) 2012-10-17
SG10201407935YA (en) 2015-01-29
MX2012006198A (es) 2012-06-19
JP2013511994A (ja) 2013-04-11
EP2470209B1 (en) 2020-01-01
US9605066B2 (en) 2017-03-28
ZA201204843B (en) 2020-02-26
JP2013511995A (ja) 2013-04-11
NZ600899A (en) 2014-09-26
MX350206B (es) 2017-08-28
BR112012012917A2 (pt) 2016-10-25
RU2012127381A (ru) 2014-01-10
US9540436B2 (en) 2017-01-10
IL219954A0 (en) 2012-07-31
RU2012127380A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
NZ607969A (en) Cd33 binding agents
PT2552955T (pt) Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios
NZ598713A (en) Insulin receptor binding antibodies
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
WO2013188693A8 (en) Antigen binding constructs to cd3
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
MY165090A (en) Antibody polypeptides that antagonize cd40
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
WO2009026117A3 (en) Novel compounds
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009131702A3 (en) Antibodies against fcrn and use thereof
PH12013502378A1 (en) Fc RECEPTOR BINDING PROTEINS
GB2488091A (en) Humanized anti-interleukin 3 receptor alpha chain antibodies
CL2012002464A1 (es) Proceso para la preparación de compuestos pesticidas que contienen un grupo tio-triazolo, que comprende hacer reaccionar un compuesto triazolo con un reactivo de grignard; compuestos pesticidas que contienen un grupo tio-triazolo; y su uso.
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201291065A1 (ru) Антитела против vla-4